Please login to the form below

Not currently logged in
Email:
Password:

non-small cell lung cancer

This page shows the latest non-small cell lung cancer news and features for those working in and with pharma, biotech and healthcare.

Novartis announces positive phase 3 trial results for advanced oesophageal cancer

Novartis announces positive phase 3 trial results for advanced oesophageal cancer

The EMA is also reviewing the drug for advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy, and in combination with chemotherapy for previously untreated advanced or metastatic ... NSCLC. BeiGene, tislelizumab’s original

Latest news

More from news
Approximately 10 fully matching, plus 677 partially matching documents found.

Latest Intelligence

  • The promise of precision medicine The promise of precision medicine

    Conditions classified as rare diseases affect a relatively small percentage of people in the world. ... The most promising results seen to date show that genetic information has helped boost the survival rates of those suffering from advanced

  • Successful product commercialisation: what can we learn from the rare disease setting? Successful product commercialisation: what can we learn from the rare disease setting?

    With an increasing number of drug trials in crowded markets such as oncology (for example, in non-small cell lung cancer and multiple myeloma), understanding patient needs is not only critical ... For novel therapies (including medicines aimed at rare

  • Unlocking the potential of precision medicine in oncology Unlocking the potential of precision medicine in oncology

    Targeted therapies. Furthermore, by following a similar trajectory in the treatment of non-small cell lung cancer (NSCLC), where we are studying specific alterations in the epidermal growth factor receptor (EGFR), ... We are following a similar approach

  • Staying ahead in the era of precision medicine Staying ahead in the era of precision medicine

    For example, Lung-MAP, a large-scale umbrella trial in non-small cell lung cancer, was one of the first to involve partnerships between several groups including the FDA, NCI, advocacy ... The challenges around precision medicine are illustrated perfectly

  • Putting commercial intelligence at the heart of strategy Putting commercial intelligence at the heart of strategy

    However, MSD’s narrow patient screening approach eventually proved to be crucial in extending overall first-line survival in non-small-cell lung cancer patients.

More from intelligence
Approximately 0 fully matching, plus 24 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • The heavy toll of COVID-19 on cancer patients

    During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. ... The therapy works predominantly on non-small cell lung cancer. The NHS has also rolled out four chemo-buses which allowed patients to take part in therapy

  • Delphi Technique Virtual Co-creation: A Customer Story

    The client’s main objectives were to:. Determine the current barriers to biomarker testing and biomarker-based treatment for non-small cell lung cancer (NSCLC), including differences in regional access and

  • Therapy Watch expands oncology and IBD portfolios

    Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and

  • Therapy Watch expands its oncology portfolio

    This month  Therapy Watch Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). ... Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL),

  • How pembrolizumab will change the management of advanced lung cancer

    The results of the Phase III KEYNOTE-024 trial of pembrolizumab for non-small cell lung cancer (NSCLC) were presented by VJOncology Editorial Board Member Dr Martin Reck of LungenClinic Grosshansdorf. ... He explains that “this data will completely

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Research Partnership

Research Partnership is now a member of Inizio Advisory, the consulting business unit of Inizio, a strategic partner for health...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....